The initial success of the copyright undeniably revolutionized the medication landscape, but investing in companies primarily reliant on generic versions presents a complex picture. Although early returns were substantial, the end of patents and the appearance of cheaper alternatives have diminished the customer base. Therefore, a thorough assessme